Tickernomics

10y

Historical Returns*:

SPY

27.80%

AXSM

10.49%

SPY

32.66%

AXSM

137.63%

SPY

108.59%

-13.74%

AXSM

SPY

302.52%

AXSM

0.00%

*Assumes dividends reinvested

Market Stats:

Market Capitalization($MM)

Enterprise Value($MM)

Daily Volume(MM)

4188.71

4055.29

0.43

Valuation Metrics:

Price/Earnings Ratio

Price/Sales Ratio

Price/Book Value

FCF Yield(%)

Dividend Yield(%)

EV/EBITDA

-13.47

12.38

45.09

-3.06

0.00

-15.44

Profitability Stats:

Operating Margin %(ttm)

Gross Profit %(ttm)

EBITDA Margin %(ttm)

-59.78

91.95

-70.66

Shareholder Value Creation:

Cost of Capital %(est)

ROIC %(ttm)

ROCE %(ttm)

Beta

8.5888

-78.55

-79.08

1.16

Other Earnings and Cash Flow Stats:

Axsome Therapeutics Inc. ( AXSM ) Net Income TTM ($MM) is -310.95

Axsome Therapeutics Inc. ( AXSM ) Operating Income TTM ($MM) is -306.06

Axsome Therapeutics Inc. ( AXSM ) Owners' Earnings Annual ($MM) is 0.00

Axsome Therapeutics Inc. ( AXSM ) Current Price to Owners' Earnings ratio is 0.00

Axsome Therapeutics Inc. ( AXSM ) EBITDA TTM ($MM) is -298.43

Axsome Therapeutics Inc. ( AXSM ) EBITDA Margin is -70.66%

Capital Allocation:

Axsome Therapeutics Inc. ( AXSM ) has paid 0.00 dividends per share and bought back -1.023323 million shares in the past 12 months

Axsome Therapeutics Inc. ( AXSM ) has increased its debt by 7.914 million USD in the last 12 months

Capital Structure:

Axsome Therapeutics Inc. ( AXSM ) Interest-bearing Debt ($MM) as of last quarter is 193

Axsome Therapeutics Inc. ( AXSM ) Annual Working Capital Investments ($MM) are -16

Axsome Therapeutics Inc. ( AXSM ) Book Value ($MM) as of last quarter is 92

Axsome Therapeutics Inc. ( AXSM ) Debt/Capital as of last quarter is 208%

Other Balance Sheet Stats:

Axsome Therapeutics Inc. ( AXSM ) has 327 million in cash on hand as of last quarter

Axsome Therapeutics Inc. ( AXSM ) has 196 million of liabilities due within 12 months, and long term debt 180 as of last quarter

Axsome Therapeutics Inc. ( AXSM ) has 48 common shares outstanding as of last quarter

Axsome Therapeutics Inc. ( AXSM ) has 0 million USD of preferred stock value

Academic Scores:

Axsome Therapeutics Inc. ( AXSM ) Altman Z-Score is 2.43 as of last quarter

Axsome Therapeutics Inc. ( AXSM ) Piotroski Score is 4.00 as of last quarter

Corporate Governance:

Axsome Therapeutics Inc. ( AXSM ) largest shareholder is owning shares at 0.00 ($MM) value

Saad Mark E(an insider) Sold 11016 shares of Axsome Therapeutics Inc. ( AXSM ) for the amount of $1005870.96 on 2024-09-11

16.61% of Axsome Therapeutics Inc. ( AXSM ) is held by insiders, and 81.19% is held by institutions

Axsome Therapeutics Inc. ( AXSM ) went public on 2015-11-19

About Axsome Therapeutics Inc. ( AXSM ) :

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that is in Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial of for treating attention-deficit/hyperactivity disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.